National Research Corporation, dba NRC Health, (NASDAQ:NRC)
today announced results for the fourth quarter 2024 and other
corporate developments.
Financial Results
Revenue for the quarter was approximately $36.9 million compared
with approximately $38.0 million in the 2023 quarter. Earnings per
diluted share were $0.28 compared with $0.36 for the 2023 quarter.
At December 31, 2024, the Company’s net indebtedness (total
borrowing minus cash and cash equivalents) was approximately $58.5
million. Total recurring contract value (TRCV) was approximately
$133.2 million at December 31, 2024.
Dividends and Stock
Repurchases
During the quarter, the Company returned approximately $10.1
million to stockholders in the form of dividends and stock
repurchases. The Company repurchased approximately 393,000 shares
for approximately $7.3 million and paid its regular quarterly
dividend of $0.12 (twelve cents) per share, or approximately $2.8
million.
About NRC Health
For more than 40 years, NRC Health (NASDAQ: NRC) has led the
charge to humanize healthcare and support organizations in their
understanding of each unique individual. NRC Health’s commitment to
Human Understanding® helps leading healthcare systems get to know
each person they serve not as point-in-time insights, but as an
ongoing relationship. Guided by its uniquely empathic heritage, NRC
Health’s patient-focused approach, unmatched market research, and
emphasis on consumer preferences are transforming the healthcare
experience, creating strong outcomes for patients and entire
healthcare systems. For more information, email info@nrchealth.com,
or visit www.nrchealth.com.
This press release contains certain statements that may be
considered forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, and such
statements are subject to the safe harbor created by those sections
and the Private Securities Litigation Reform Act of 1995, as
amended. Such statements may be identified by their use of terms or
phrases such as “believes,” “expect,” “focus,” “potential,” “will,”
derivations thereof, and similar terms and phrases. In this press
release, the statements related to future dividends are
forward-looking statements. Forward-looking statements are based
upon the current beliefs and expectations of our management and are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified, which could cause future events and
actual results to differ materially from those set forth in,
contemplated by, or underlying the forward-looking statements,
including those risks and uncertainties as set forth in the Risk
Factors section of our Annual Report on Form 10-K for the year
ended December 31, 2023, and various disclosures in our press
releases, stockholder reports, and other filings with the
Securities and Exchange Commission. We disclaim any obligation to
update or revise any forward-looking statements to reflect actual
results or changes in the factors affecting the forward-looking
information.
© NRC Health
NATIONAL RESEARCH CORPORATION
AND SUBSIDIARY
Unaudited Condensed
Consolidated Statements of Income
(In thousands, except per share
data)
Three months ended
Twelve months ended
December 31
December 31
2024
2023
2024
2023
Revenue
$
36,907
$
38,001
$
143,060
$
148,580
Operating expenses:
Direct
14,350
13,793
56,933
56,015
Selling, general and administrative
11,452
11,070
44,911
46,621
Depreciation and amortization
1,516
1,429
6,022
5,899
Total operating expenses
27,318
26,292
107,866
108,535
Operating income
9,589
11,709
35,194
40,045
Other income (expense):
Interest income
22
41
125
820
Interest expense
(729
)
(269
)
(2,595
)
(862
)
Other, net
(6
)
(13
)
(34
)
(41
)
Total other income (expense)
(713
)
(241
)
(2,504
)
(83
)
Income before income taxes
8,876
11,468
32,690
39,962
Provision for income taxes
2,315
2,610
7,907
8,991
Net income
$
6,561
$
8,858
$
24,783
$
30,971
Earnings Per Share of Common Stock:
Basic Earnings Per Share
$
0.28
$
0.36
$
1.05
$
1.26
Diluted Earnings Per Share
$
0.28
$
0.36
$
1.04
$
1.25
Weighted average shares and share
equivalents outstanding:
Basic
23,354
24,437
23,703
24,540
Diluted
23,366
24,548
23,743
24,673
NATIONAL RESEARCH CORPORATION
AND SUBSIDIARY
Unaudited Condensed
Consolidated Balance Sheets
(Dollars in thousands, except
share amounts and par value)
December 31,
December 31,
2024
2023
Assets
Current assets:
Cash and cash equivalents
$
4,233
$
6,653
Accounts receivable, net
11,054
12,378
Other current assets
4,313
5,329
Total current assets
19,600
24,360
Property and equipment, net
38,269
28,205
Goodwill
66,152
61,614
Other, net
8,518
8,258
Total assets
$
132,539
$
122,437
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of notes payable, net of
unamortized debt issuance costs
$
4,789
$
7,214
Accounts payable and accrued expenses
6,825
6,194
Accrued compensation
4,774
3,953
Deferred revenue
15,786
14,834
Dividends payable
2,770
2,906
Other current liabilities
914
1,102
Total current liabilities
35,858
36,203
Notes payable, net of current portion and
unamortized debt issuance costs
57,895
29,470
Other non-current liabilities
7,502
7,809
Total liabilities
101,255
73,482
Shareholders’ equity:
Preferred stock, $0.01 par value,
authorized 2,000,000 shares, none issued
--
--
Common stock, $0.001 par value; authorized
110,000,000 shares, issued 31,072,144 in 2024 and 31,002,919 in
2023, outstanding 23,083,116 in 2024 and 24,219,887 in 2023
31
31
Additional paid-in capital
180,249
178,213
Retained earnings (accumulated
deficit)
(17,064
)
(30,530
)
Treasury stock
(131,932
)
(98,759
)
Total shareholders’ equity
$
31,284
$
48,955
Total liabilities and shareholders’
equity
$
132,539
$
122,437
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250127637796/en/
Michelle Bachman 402-475-2525
National Research (NASDAQ:NRC)
過去 株価チャート
から 1 2025 まで 2 2025
National Research (NASDAQ:NRC)
過去 株価チャート
から 2 2024 まで 2 2025